home / stock / acst:cc / acst:cc news

ACST:CC News and Press, Acasti Pharma Inc. From 11/04/22

Stock Information
Company Name: Acasti Pharma Inc.
Stock Symbol: ACST:CC
Market: TSXVC
Website: acastipharma.com
Menu
ACST:CC ACST:CC Quote ACST:CC Short ACST:CC News ACST:CC Articles ACST:CC Message Board
Get ACST:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
ACST:CC - Acasti Pharma Inc. (NASDAQ:ACST) (TSX.V:ACST) Featured in Coverage of Investor Summit Group's Q4 Event

Acasti Pharma (NASDAQ: ACST) (TSX.V: ACST) is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases. Acasti’s novel drug candidates have the potential to improve the performance of currently marketed drugs by achieving fas...
ACST:CC - Acasti Announces Court Dismissal of Stockholder Litigation

LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announ...

ACST:CC - Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“ Acasti ” or the “ Company ”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan dise...

ACST:CC - Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announ...
ACST:CC - Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, ph...

ACST:CC - Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today ...

ACST:CC - Acasti Pharma Reports First Quarter 2023 Operational Results

LAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today a...
ACST:CC - Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 ...

ACST:CC - Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia

LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 c...

ACST:CC - Acasti Pharma Announces Annual Grants of Performance Stock Options

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today a...
Previous 10 Next 10